Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Dec 07, 2022 4:23pm
Ifenprodil granted Orphan Drug Designation
On Monday Algernon Pharmaceuticals (AGN.c AGNPF), shared that the U.S. FDA granted Orphan Drug Designation to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF). Ifenprodil is the
...more
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Comment by
XeniaTechie
on Dec 06, 2022 1:21pm
RE:AGN.c has been granted Orphan Drug Designation to Ifenprodil
Major catalyst alert re: Algernon’s recent news being granted orphan drug designation by the FDA for its use of Ifenprodil as a treatment for IPF. FDA orphan drug designation is massive due to the
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Dec 05, 2022 6:49pm
AGN.c has been granted Orphan Drug Designation to Ifenprodil
AGN.c has been granted Orphan Drug Designation to Ifenprodil for treatment of Pulmonary fibrosis. https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-receives-u-fda-120000269
...more
(86)
•••
yopmemama021
X
View Profile
View Bullboard History
Post by
yopmemama021
on Dec 05, 2022 6:13pm
AGN
big day for AGN.c shot up 22.3% on news : just received U.S. FDA Orphan drug designation for their IPF treatment ( Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 05, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug...
read article.
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Dec 01, 2022 2:50pm
CEO Interview
The CEO of AGN.v AGNPF was recently featured on Market One to discuss their investigation into DMT as a treatment for strokes. Some highlights that stood out to me - Currently only around 15% of
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Nov 30, 2022 5:07pm
DMT phase 1 study begins screening doseing to start in Dec
Algernon Pharmaceuticals Inc. (AGN.c AGNPF), has started screening subjects for its Phase 1 clinical study of IV DMT for the treatment of stroke. AGN should dose the first subject of the
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 29, 2022 5:29pm
AGN.c is currently two weeks into Phase 1 clinical trials fo
AGN.c is currently two weeks into Phase 1 clinical trials for DMT treatment of stroke. https://twitter.com/top_prospector/status/1597292188987453440 Phase 1's object is
...more
(40)
•••
StockDoctor101
X
View Profile
View Bullboard History
Post by
StockDoctor101
on Nov 28, 2022 12:54pm
Looking at AGN @ $2.47
I like the tight float of AGN. Seems to be holding around $2.5 but some promising results from their DMT trials could get it moving again. Phase II trials could also start as early as next year on
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Nov 25, 2022 1:00pm
Article on AGN
Came across this article on the potential for DMT to become a breakthrough treatment for people who suffer a stroke. It also touches on AGN.c AGNPF and their phase-1 study they began earlier this
...more
(22)
•••
GoodLife60
X
View Profile
View Bullboard History
Post by
GoodLife60
on Nov 25, 2022 11:35am
Did I miss a news release?
Why is this dropping this time.
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Nov 24, 2022 1:46pm
Video with CEO
Found this video of the AGN.c AGNPF CEO featured on Market One discussing their investigation into DMT as a treatment for strokes. Some noteworthy things mentioned - Currently only around 15% of
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Nov 23, 2022 3:03pm
AGN Begins Screening for Phase 1 Study
AGN.c AGNPF announced last week they began screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (DMT). The decision to investigate DMT and move it into human
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 22, 2022 5:49pm
Expecting AGN.c to reach phase 2 of DMT trials swiftly.
Expecting AGN.c to reach phase 2 of DMT trials swiftly. AGN.c has started screening subjects for its phase 1 clinical trials, since a few DMT trials at this stage have already
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 21, 2022 6:44pm
AGN.c starting to stabilize in the high $2 range.
AGN.c starting to stabilize in the high $2 range. https://twitter.com/StckMasterFlash/status/1592966259284799488 As we have seen in the past they're price can jump
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed
EnviroGold Global Announces Appointment of Chief Operating Officer